Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | HPSE | Q9Y251 | 8/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | DDX3X | O00571 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL980449 | 0.92 | KMT2A (0.69) | RAB9ANPC1TP53MAPTKMT2A | |
| SCHEMBL981812 | 0.81 | MAPT (0.78) | RAB9ANPC1TP53MAPTKMT2A | |
| SCHEMBL2739970 | 0.78 | HPSE (0.65) | RAB9ANPC1MAPTHPSEKMT2A | |
| SCHEMBL6259761 | 0.78 | NPC1 (0.71) | RAB9ANPC1MAPTHPSEKMT2A | |
| SCHEMBL12388199 | 0.77 | NPC1 (1.00) | RAB9ANPC1TP53MAPTKMT2A | |
| SCHEMBL980581 | 0.76 | CASP3 (0.59) | RAB9ANPC1TP53MAPTKMT2A | |
| SCHEMBL2740090 | 0.76 | HPSE (0.73) | RAB9ANPC1TP53MAPTHPSE | |
| SCHEMBL2246214 | 0.76 | HPSE (0.83) | RAB9ANPC1TP53MAPTHPSE | |
| SCHEMBL980108 | 0.76 | CASP3 (0.86) | RAB9ANPC1TP53MAPTKMT2A | |
| SCHEMBL25674724 | 0.75 | KMT2A (0.63) | RAB9ANPC1MAPTHPSEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642788-B2 | Activators of executioner procaspases 3, 6 and 7 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-04 | — | — | US | disclosed |
| US-20110021522-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021522-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021522-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | CASP7, CASP3, CASP6 | RAB9A 3095/4885NPC1 2565/4885TP53 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.